#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4248	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2617	475.6	0	.	n	.	0	A69G	SNP	69	69	A	513	513	G	565	G,A	531,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4248	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2617	475.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1894	1894	T	650	T	599	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4248	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2617	475.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1628	1628	C	596	C,G,A	542,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4248	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2617	475.6	0	HET	.	.	.	C1358T	.	1358	1358	C	1802	1802	C	677	C,T	506,114	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4105	520.3	0	.	n	.	0	T695C	SNP	695	695	T	1291	1291	C	522	C,T	462,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4105	520.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2567	2567	C	743	C,T,A	668,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4105	520.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3193	3193	T	617	T,G	549,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4105	520.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2641	2641	A	750	A,C	688,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	706	folP	855	855	100.0	folP.l15.c4.ctg.1	1960	107.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1218	1220	AGC	132;133;135	A;G;C	114;119;117	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1380	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3895	106.1	1	SNP	p	S91F	1	.	.	271	273	TTC	819	821	TTC	104;102;103	T;T;C	92;93;94	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1380	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3895	106.1	1	SNP	p	D95G	1	.	.	283	285	GGC	831	833	GGC	102;102;103	G;G;C	93;91;95	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1380	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3895	106.1	1	SNP	p	G95N	0	.	.	283	285	GGC	831	833	GGC	102;102;103	G;G;C	93;91;95	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	666	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1827	108.8	0	.	p	.	0	D79N	NONSYN	235	237	GAT	827	829	AAT	197;198;200	A;A;T	175;178;176	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	666	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1827	108.8	1	SNP	p	G45D	0	.	.	133	135	GGC	725	727	GGC	170;169;170	G,T;G;C	156,1;159;163	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	414	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1399	87.8	0	.	n	.	0	A197.	DEL	197	197	A	781	781	A	147	A	139	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	0	.	p	.	0	E91G	NONSYN	271	273	GAG	707	709	GGG	155;154;156	G;G;G	140;136;138	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	1	SNP	p	D86N	0	.	.	256	258	GAC	692	694	GAC	153;152;153	G,C;A,C;C	137,1;132,1;138	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	1	SNP	p	S87R	0	.	.	259	261	AGT	695	697	AGT	153;153;153	A;G;T	134;135;138	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	1	SNP	p	S87I	0	.	.	259	261	AGT	695	697	AGT	153;153;153	A;G;T	134;135;138	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	1	SNP	p	S87W	0	.	.	259	261	AGT	695	697	AGT	153;153;153	A;G;T	134;135;138	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3233	139.1	1	SNP	p	S88P	0	.	.	262	264	TCC	698	700	TCC	153;153;152	T;C;C	135;136;139	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1262	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3242	116.7	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1878	1880	CAC	149;148;149	C;A;C	139;137;142	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1262	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3242	116.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1827	1829	GGC	162;163;165	G;G;C,A	147;149;149,2	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1496	1498	GCA	184;184;185	G,A;C,G;A	164,1;165,1;165	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1499	1501	ATC	186;184;184	A,C;T,C;C	166,1;158,2;166	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1511	1513	GTG	181;180;181	G;T;G,T	167;157;162,1	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1511	1513	GTG	181;180;181	G;T;G,T	167;157;162,1	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2015	2017	ACC	148;148;148	A;C,A;C	135;131,1;136	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2069	2071	ACG	142;142;140	A,G,C;C,G,A;G	114,2,1;114,1,1;118	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2069	2071	ACG	142;142;140	A,G,C;C,G,A;G	114,2,1;114,1,1;118	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2192	2194	GGC	149;152;152	G,C;G;C	119,1;128;131	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2201	2203	GGC	152;149;150	G;G;C	123;127;124	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1202	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	127.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2219	2221	CTG	147;149;148	C;T;G	124;121;128	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1538	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3738	123.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1956	1958	CCG	128;128;128	C;C;G,A	119;115;119,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	738	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2404	92.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	846	846	C	123	C,T,G	110,1,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1395	1397	AAT	15;15;15	A;A;T	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1398	1400	AAT	15;15;15	A;A;T	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1422	1424	GCA	12;12;12	G;C;A	10;9;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1445	1447	GTA	11;11;11	G;T;A	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1451	1453	AAC	11;11;11	A;A;C	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1455	1459	TGGCG	11;11;11;10;10	T;G;G;C;G	11;11;11;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1461	1463	GCT	10;10;10	G;C;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1521	1523	TTA	9;9;9	T;T;A	8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1566	1568	CAT	9;9;9	C;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1569	1571	AGT	9;9;9	A;G;T	9;8;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	136	porB1a	984	297	90.37	porB1a.l15.c4.ctg.1	1669	23.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1578	1580	TAC	9;9;9	T;A;C	9;9;9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	T26A	NONSYN	76	78	ACC	762	764	GCC	210;211;211	G,A;C;C	181,1;188;188	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	798	800	GAA	203;203;201	G,C;A,T;A	185,1;188,1;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	N124S	NONSYN	370	372	AAT	1056	1058	AGT	196;195;194	A;G;T,G	173;172;168,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1086	1088	GAT	185;185;185	G;A;T	170;165;167	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1209	1211	TCA	181;182;182	T;C,T;A	163;167,1;164	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	D212Y	NONSYN	634	636	GAT	1320	1322	TAT	164;165;164	T;A;T	144;148;141	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1338	1340	GTC	152;152;152	G;T;C,T	138;143;141,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1350	1352	TCT	155;154;155	T;C;T	143;145;144	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1668	1670	GCA	167;167;165	G,T;C,T;A,C	148,1;149,1;156,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	1	SNP	p	G120K	1	.	.	358	360	AAG	1044	1046	AAG	199;199;199	A;A;G	171;173;171	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	1	SNP	p	A121D	1	.	.	361	363	GAC	1047	1049	GAC	199;198;198	G;A;C,A	172;174;172,2	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	924	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2194	125.4	1	SNP	p	D121N	0	.	.	361	363	GAC	1047	1049	GAC	199;198;198	G;A;C,A	172;174;172,2	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2778	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5472	152.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2404	2406	CAT	156;156;157	C;A,G,C;T,G	145;142,1,1;145,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	464	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1695	82.0	1	SNP	p	V57M	1	.	.	169	171	ATG	909	911	ATG	164;164;163	A;T;G	150;151;149	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
